Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 2 repotrectinib 1 pralsetinib 1 pembrolizumab 1 entrectinib 1 copper dotatate CU-64 1 cabozantinib 1 X-Rays 1 Specimen Handling 1 Phantoms, Imaging 1 Octreotide 1 Magnetic Resonance Spectroscopy 1 Lutetium-177 1 Lutetium 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Octreotide × NET × Clear all

NCT01578239 2022-04-04

NETTER-1

Advanced Accelerator Applications

Phase 3 Completed

231 enrolled 16 charts 2 FDA

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡